University of Texas Medical School, Texas, USA
Talk Title: Maternal Immunization: The Road Less Traveled.
Dr. Baker is professor of pediatrics at University of Texas Medical School in Houston, and formerly professor of pediatrics, molecular virology and microbiology at Baylor College of Medicine (BCM) from 1975-2018.
View full bio
Dr. Baker made groundbreaking recognition of neonatal and young infant group B streptococcal disease and its correlation to lack of maternal antibodies to the GBS capsular polysaccharide during her infectious diseases fellowship training at BCM and Harvard Medical School. She subsequently expanded knowledge of the changing epidemiology of neonatal sepsis, and GBS pathogenesis and prevention strategies. Her work with Dennis L. Kasper led to NIH-funded research of candidate GBS vaccines and clinical trials, and her advocacy work first with the American Academy of Pediatrics in 1992 and then with the U.S. Centers for Disease Control and Prevention (CDC) in 1996 led to routine culture screening of pregnant women for GBS colonization and intrapartum antibiotic prophylaxis, a policy that has been implemented in several European countries and resulted in a more than 80% reduction of GBS disease in the U.S.. A pioneer in advocating for maternal immunization, the recommendation for routine pertussis booster immunization during every pregnancy was made during her time as Chair of the Advisory Committee for Immunization Practices to the CDC, 2009-2012.
Dr. Baker is the author or co-author of more than 400 peer reviewed publications, book chapters, reviews and editorials. She was an editor of 5 editions of the AAP Red Book. A committed clinician and teacher, she has received several awards and mentored dozens of pediatric infectious diseases trainees. A few of her many awards include the Maurice Hilleman Award from the CDC, and the Mentor and Alexander Fleming Lifetime Achievement Awards from the Infectious Diseases Society of America.
Kaiser Permanente, USA
Talk Title: Effective interventions to improve vaccine-related attitudes and increase vaccine acceptance
Dr. Matthew F. Daley is a practicing pediatrician and a researcher with over 18 years’ experience conducting complex multi-site pediatric health services research, primarily related to vaccine safety, vaccine services delivery, and parental vaccine hesitancy. Since 2007, Dr. Daley has been an investigator in the Vaccine Safety Datalink (VSD) project.
View full bio
The VSD, a long-standing collaboration between the U.S. Centers for Disease Control and Prevention and 9 large integrated health care organizations, investigates the safety of all vaccines licensed in the U.S. Dr. Daley was one of the lead researchers involved in producing a White Paper examining the feasibility of studying the safety of the routine U.S. vaccination schedule in the VSD. Dr. Daley has studied parental vaccine hesitancy from the perspective of parents as well as health care providers. Working with a colleague, Dr. Jason Glanz, Dr. Daley has recently conducted a randomized controlled trial of a social media intervention designed to address parental vaccine hesitancy. The intervention, involving interactive social media tools as well as detailed internet-based curated material, significantly improved parents’ vaccine-related attitudes, and significantly improved vaccination timeliness. Dr. Daley is a Senior Investigator at the Institute for Health Research at Kaiser Permanente Colorado (KPCO). KPCO is the largest non-profit health care entity in the U.S. state of Colorado, serving approximately 670,000 members. Dr. Daley is also an Associate Professor of Pediatrics at the University of Colorado School of Medicine.
Murdoch Children's Research Institute, Australia
Margie is a senior research fellow at the MCRI and a consultant paediatrician at the Royal Children’s Hospital, Department of Paediatrics. She has extensive expertise in vaccine research focused on clinical trials, vaccine safety and vaccine social science.
View full bio
Her primary research focus has shifted to developing new interventions to improve vaccine confidence and uptake amongst different populations and in different settings, including pregnancy, primary care, for high risk children and in developing country settings. She aims to provide a solid evidence base to inform vaccine policy in Australia to support the least restrictive vaccine mandates that will still ensure high vaccine coverage for Australian children. Margie is now a trusted and public face of vaccine confidence and acceptance in Australia with a prominent role in the media. She has international collaborations with leading researchers in the area and is invited to speak at national and international conferences on vaccine confidence.
Animal and Plant Health Agency, UK
Talk Title: Current status of rabies and prospects for the reduction of human rabies cases by 2030
My current role is Lead Scientist for International Development at The Animal and Plant Health Agency in the UK, an agency of the UK Department for Environment, Food and Rural Affairs.
View full bio
Since 2002, I was appointed director of a World Health Organisation Communicable Disease Surveillance and Response Collaborating Centre for the characterisation of rabies and rabies-related viruses. In 2006, I was appointed a Designated OIE Reference Expert for Rabies. I am an Honorary Visiting Professor in the Department of Veterinary Pathology at the University of Liverpool, UK and at St George’s University of London, UK. In 2018, I was elected as a member of the International Committee for the Taxonomy of Viruses (ICTV) Rhabdovirus Study Group. I currently have active research principally focused on RNA viruses, especially viral diseases of the CNS and emerging / exotic viral zoonoses. I have published more than 300 manuscripts in international journals and am an Associate Editor for the journal, Vaccine.
World Health Organization, Switzerland
Talk Title: Disease eradication in human populations: challenges and opportunities
View full bio
More information coming soon
Icahn School of Medicine at Mount Sinai, New York, USA
Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna, Austria. He received his postdoctoral training in the laboratory of Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines.
View full bio
In 2013 he became an independent principal investigator and is currently Associate Professor at the Icahn School of Medicine at Mount Sinai. Dr. Krammer's work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on Zika virus, hantaviruses, filoviruses and arenaviruses.
Stanley A. Plotkin
Emeritus Professor of the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University
Talk Title: Current problems in Vaccinology
Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University.
View full bio
Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. He maintained laboratories at both CHOP and Wistar. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught (now called Sanofi Pasteur), where for seven years he was Medical and Scientific Director, based at Marnes-la-Coquette, outside Paris. He left France in 1998, and is now consultant to many vaccine manufacturers, biotechnology companies and non-profit research organizations as principal of Vaxconsult. He also continues to teach at the University of Pennsylvania.
Gregory A. Poland
Editor in Chief, Vaccine and Mayo Clinic, USA
Gregory A. Poland, M.D., studies the immunogenetics of vaccine response in adults and children. Dr. Poland and his team within the Vaccine Research Group aim to improve the health of individuals across the world by pursuing challenges posed by infectious diseases and bioterrorism through clinical, laboratory and epidemiologic vaccine research.
View full bio
The Vaccine Research Group uses immunological testing, including serology, cell-mediated immunity, cell culture and cytokine assays; polymerase chain reaction (PCR) techniques and HLA typing for immunogenetic studies; and high-throughput assays, such as next-generation sequencing, transcriptomics, mass spectrometry and proteomic analysis.
Dr. Poland's research has been continuously funded by the National Institutes of Health since 1991.
What is "vaccinomics?"
Coined by Dr. Poland and his team in 2007, the term "vaccinomics" refers to the development of personalized vaccines based on the increased understanding of immune response phenotype-genotype information. Through research, Dr. Poland and his team aim to explain how vaccine-induced immune responses and vaccine-related adverse events may be genetically determined — and therefore predictable.
Independent Consultant, UK
Talk Title: Rinderpest eradication: Lessons learned
I am a veterinarian with broad experience of disease epidemiology, diagnosis and control.
View full bio
In particular I have specialist expertise and extensive practical experience of bringing together disciplines relating to the control of infectious and especially epizootic and zoonotic diseases, namely; disease investigation; virology; laboratory diagnostics; epidemiology; reporting and surveillance systems; disease control procedures; official veterinary service structures and functions, national strategic planning; and emergency preparedness planning.
During my career I have conducted research on the pathogenesis of pestiviruses and bluetongue virus, the epidemiology of morbilliviruses and foot-and-mouth disease. I have broad experience of virtually all the major infectious diseases of livestock including foot-and-mouth disease; rinderpest; avian influenza; Newcastle disease; peste des petits ruminants; Rift Valley fever; bluetongue; African horse sickness; classical swine fever; African swine fever; capripox; lumpy skin disease; rabies; malignant catarrhal fever, contagious bovine pleuropneumonia; contagious caprine pleuropneumonia; haemorrhagic septicaemia; brucellosis; anthrax; tuberculosis and bovine spongiform encephalopathy.
I have lived and worked on long term assignments for 12 years in developing countries in Africa and Asia and was based in Rome for 14 years for the Food and Agriculture Organization of the United Nations from where I traveled extensively to work in some 70 countries in Africa, Asia, the Americas, the Caribbean and Europe. Most notably for FAO I worked on the international coordination of control of transboundary animal disease epidemics, especially rinderpest, from 1994 to 2007 and was executive Secretary of the Global Rinderpest Eradication Programme from 2000 to 2007. Consequently I have an extensive knowledge of the conditions which prevail in developing countries and countries in transition and disease control practices. On reaching mandatory UN retirement age in June 2007 I retired from FAO and now work as a UK-based independent consultant.
John Hopkins University, USA
Daniel Salmon is a Professor of International Health and Health, Behavior & Society, and Deputy Director of the Institute for Vaccine Safety, Johns Hopkins University Bloomberg School of Public Health.
View full bio
Dr. Salmon’s primary research and practice interest is optimizing the prevention of childhood infectious diseases through the use of vaccines. He is broadly trained in vaccinology, with an emphasis in epidemiology, behavioral epidemiology, and health policy. Dr. Salmon’s focus has been on determining the individual and community risks of vaccine refusal, understanding factors that impact vaccine acceptance, evaluating and improving state laws providing exemptions to school immunization requirements, developing systems and science in vaccine safety, and effective vaccine risk communication. Dr. Salmon has considerable experience developing surveillance systems, using surveillance data for epidemiological studies, and measuring immunization coverage through a variety of approaches. Dr. Salmon has worked with state and federal public health agencies to strengthen immunization programs and pandemic planning.